NYXOAH SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.56 EUR | +2.64% |
|
+5.68% | +100.94% |
| May. 24 | HC Wainwright Adjusts Nyxoah SA Price Target to $18 From $22, Maintains Buy Rating | MT |
| May. 23 | Nyxoah Reduces Shares Available Under At the-Market Offering Program | MT |
| Sales 2024 * | 8.3M 9M | Sales 2025 * | 33.47M 36.3M | Capitalization | 294M 319M |
|---|---|---|---|---|---|
| Net income 2024 * | -55M -59.65M | Net income 2025 * | -71M -77M | EV / Sales 2024 * | 29.1 x |
| Net cash position 2024 * | 52.9M 57.37M | Net Debt 2025 * | 16.5M 17.89M | EV / Sales 2025 * | 9.28 x |
| P/E ratio 2024 * |
-4.78
x | P/E ratio 2025 * |
-4.39
x | Employees | 147 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 42.76% |
More Fundamentals
* Assessed data
More news
Latest transcript on Nyxoah SA
More recommendations
More press releases
| 1 day | +2.64% | ||
| 1 week | +5.68% | ||
| 1 month | -8.15% | ||
| 3 months | -32.60% | ||
| 6 months | +88.13% | ||
| Current year | +100.94% |
1 week
7.80
8.60
1 month
7.6611.40
Current year
3.7917.60
1 year
3.7917.60
3 years
3.7930.00
5 years
3.7930.00
10 years
3.7930.00
| Managers | Title | Age | Since |
|---|---|---|---|
Olivier Taelman
CEO | Chief Executive Officer | 54 | 19-06-30 |
Robert Taub
FOU | Founder | 78 | 09-07-14 |
Loïc Moreau
DFI | Director of Finance/CFO | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kevin Rakin
BRD | Director/Board Member | 63 | 16-06-28 |
Robert Taub
FOU | Founder | 78 | 09-07-14 |
Jürgen Hambrecht
BRD | Director/Board Member | 77 | 15-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 8.56 | +2.64% | 53,065 |
| 24-05-30 | 8.34 | +3.22% | 38,238 |
| 24-05-29 | 8.08 | +0.50% | 52,463 |
| 24-05-28 | 8.04 | -4.74% | 87,144 |
| 24-05-27 | 8.44 | +4.20% | 53,436 |
Real-time Euronext Bruxelles, May 31, 2024 at 11:37 am EDT
More quotes
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah SA's innovative solution platform is based on the Genio® system, a CE-Mark validated, user-centered neurostimulation therapy for obstructive sleep apnea, the world's most common sleep disordered breathing condition.
Calendar
2024-06-12
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
8.56
EUR
Average target price
15.5
EUR
Spread / Average Target
+81.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +100.94% | 319M | |
| +7.01% | 217B | |
| +11.01% | 190B | |
| +19.20% | 143B | |
| +30.79% | 111B | |
| +1.48% | 64.59B | |
| +13.95% | 52.36B | |
| -0.16% | 48.45B | |
| -6.20% | 38.03B | |
| +0.91% | 35.61B |
- Stock Market
- Equities
- NYXH Stock
